Physician profile
Gilbert G Ching
NPI 1659527497
$7,966.39
in general payments reported to CMS, 2019-2025
36 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $260 · 2021: $238 · 2022: $1,389 · 2023: $1,880 · 2024: $1,611 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,640 · Education: $17.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,639.70 |
| Education | $17.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $776.11 | 2022-2025 | Watchman Flx, Watchman Access System, Watchman |
| Amgen INC. | $774.83 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $711.28 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $702.15 | 2019-2025 | |
| Pfizer INC. | $680.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $588.48 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $514.10 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $411.71 | 2019-2025 | Jot Dx, Aveir, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.74 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $344.91 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $248.84 | 2019-2024 | Farxiga |
| Impulse Dynamics (USA) INC. | $218.85 | 2022-2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $210.75 | 2022-2023 | Amvuttra, Onpattro |
| Heartflow, INC. | $187.41 | 2023-2025 | Ffrct |
| Sanofi-Aventis U.S. LLC | $159.11 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $154.33 | 2019-2024 | Uptravi, Opsumit |
| Biotronik INC. | $152.94 | 2022 | |
| Amarin Pharma, INC. | $152.72 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $129.47 | 2019-2024 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $86.57 | 2023-2024 | Inpefa |
| Abiomed | $40.32 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.60 | 2019-2024 | Lifevest |
| Scpharmaceuticals INC. | $35.65 | 2023 | |
| Cvrx, INC. | $34.19 | 2023 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $34.12 | 2024 | Arcalyst |
| Lundbeck LLC | $33.67 | 2019 | |
| Corcept Therapeutics | $31.20 | 2021 | |
| Vifor Pharma, INC. | $24.53 | 2019 | |
| Azurity Pharmaceuticals, INC. | $21.05 | 2023 | Edarbyclor |
| Lilly USA, LLC | $20.19 | 2025 | Mounjaro |
| Arbor Pharmaceuticals, INC. | $19.78 | 2019 | |
| Astellas Pharma US INC | $19.73 | 2019 | |
| Preventice Services, LLC | $19.26 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $18.52 | 2023 | Arcalyst |
| Allergan, INC. | $13.95 | 2019 | |
| Gilead Sciences, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Ching listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.